Ny forskning afslører en skræmmende sammenhæng mellem vægttabsmedicinen Ozempic og Wegovy og en alvorlig øjenlidelse, der kan føre til blindhed. Læs mere her!
Ny forskning har sat fokus på en potentiel forbindelse mellem Novo Nordisks GLP-1-medicin Ozempic og Wegovy og en alvorlig øjensygdom kaldet NAION. En ledende undersøgelse fra Massachusetts Eye and Ear viser, at personer ordineret semaglutid, solgt som Ozempic og Wegovy, har en øget risiko for at udvikle denne øjenlidelse. NAION kan medføre irreversible synstab og er en sjælden, men alvorlig komplikation. Undersøgelser tyder på, at personer med diabetes, der tager disse medikamenter, har fire gange større risiko for at blive diagnosticeret med sygdommen i synsnerven. Resultater offentliggjort i JAMA Ophthalmology indikerer, at brugen af Wegovy (semaglutid) potentielt kan øge forekomsten af NAION hos diabetespatienter. Det er afgørende at være opmærksom på risiciene ved disse populære vægttabsmediciner for at undgå alvorlige synproblemer.
A new study reports for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition, NAION.
A new Mass Eye and Ear-led study is the first to discover that people prescribed semaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a ...
People taking Ozempic and Wegovy may be at increased risk of developing a debilitating eye condition that can cause irreversible vision loss, ...
Use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) may be linked with an increased risk of the second most common form of optic neuropathy, a ...
An original investigation published in JAMA Ophthalmology indicated that the megablockbuster metabolic medication Wegovy (semaglutide) may increase the risk ...
People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve.
Patients using Novo Nordisk's wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a ...
Those who take Ozempic or Wegovy may have an increased risk of developing a rare form of blindness, though future research is needed to make a final ...
Experts agree that the potential risk of NAION should not deter the use of semaglutide medications to treat diabetes or obesity. “In the ever-changing landscape ...
A new study reveals that patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss have a higher risk of developing NAION, ...